Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
Anastrozole is a nonsteroidal aromatase inhibitor that compounding pharmacies prepare as oral capsules and other oral forms in strengths not manufactured, by prescription.
Anastrozole is a selective, nonsteroidal aromatase inhibitor. Aromatase converts androgens made in the adrenal glands, fat and testes into estrogens; blocking it lowers circulating estradiol markedly within a day of the first dose. The manufactured product is Arimidex (anastrozole tablets, ANI Pharmaceuticals) and its generics, a single-strength oral tablet. It is FDA-approved for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, first-line treatment of postmenopausal women with hormone receptor-positive or receptor-unknown locally advanced or metastatic breast cancer, and treatment of advanced breast cancer in postmenopausal women after progression on tamoxifen. No manufactured product exists in a lower strength or as a liquid, so a prescriber might order compounded anastrozole for a fractional strength, a divided or infrequent schedule, or a patient who cannot swallow tablets. Compounded preparations are not FDA-approved and require a prescription.
Arimidex carries no boxed warning. Do not use it after a serious allergic reaction to anastrozole; anaphylaxis, angioedema and hives have occurred. Because it lowers estrogen, it thins bone and raises fracture risk, raises cholesterol in some people, and in women with existing heart disease was linked to more ischemic heart events than tamoxifen. It can harm an unborn baby; people who can become pregnant need contraception during treatment and for three weeks after the last dose, and the label says not to breastfeed during treatment or for two weeks after it. Do not combine it with tamoxifen or with estrogen products, including hormone replacement or birth control pills. Common side effects are hot flashes, weakness, joint pain and stiffness, nausea, headache, mood changes, sleep trouble and hair thinning. Call your prescriber for chest pain, yellowing skin or eyes, blistering rash, facial swelling or trouble breathing. If side effects bother you, talk to your prescriber or pharmacist.
Anastrozole is a potent, selective triazole aromatase inhibitor that suppresses peripheral conversion of androstenedione and testosterone to estrone and estradiol without progestogenic, androgenic or estrogenic activity. Oral absorption is rapid, with peak levels within about 2 hours fasting; food slows but does not reduce absorption. Protein binding is about 40 percent, steady state is reached in about 7 days, metabolism is hepatic to an inactive triazole metabolite, elimination is about 85 percent hepatic and 10 percent renal, and the mean elimination half-life is about 50 hours. Labeled indications (Arimidex tablets): adjuvant, first-line and second-line therapy of hormone receptor-positive breast cancer in postmenopausal women; pediatric trials in pubertal gynecomastia and McCune-Albright precocious puberty did not demonstrate efficacy, and the label lists no indication in men. Prescribers have ordered compounded anastrozole for hypogonadal or subfertile men with elevated estradiol or a low testosterone-to-estradiol ratio, a use examined in a 2019 systematic review and meta-analysis (Del Giudice et al., Asian Journal of Andrology) and a 2021 retrospective series (Shah et al., Translational Andrology and Urology); both call the evidence limited and call for randomized trials. Dosing, strength and interval are per prescriber. Monitor bone mineral density, lipids, estradiol and testosterone in men, liver enzymes and cardiovascular symptoms. Avoid tamoxifen (lowers exposure by about 27 percent) and estrogens. Not a controlled substance.
Swallow each capsule whole with a glass of water, unless your label says otherwise. Do not crush, chew or open the capsule unless your pharmacist tells you it is safe to do so. Take it at the times shown on your prescription label. If you miss a dose or are unsure how to take it, call the pharmacy.
Capsules are nonaqueous, so under USP <795> they usually carry a beyond-use date of up to 180 days when no other stability data apply. Keep the vial tightly closed at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard any capsules left after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
